Spots Global Cancer Trial Database for phesgo
Every month we try and update this database with for phesgo cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer | NCT05306041 | HER2-positive B... | Inavolisib PHESGO Endocrine thera... | 18 Years - | German Breast Group | |
| A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | NCT05296798 | Locally Advance... | Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocr... | 18 Years - | Hoffmann-La Roche | |
| Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade | NCT06068985 | Breast Cancer HER2-positive B... | PHESGO | 18 Years - 80 Years | Latin American Cooperative Oncology Group | |
| A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | NCT05296798 | Locally Advance... | Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocr... | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | NCT05894239 | Metastatic Brea... | Inavolisib Phesgo Placebo Taxane-based Ch... Optional Endocr... | 18 Years - | Hoffmann-La Roche | |
| The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | NCT06439693 | Breast Cancer F... Breast Cancer Breast Cancer M... Estrogen Recept... HER2-positive B... Stage IV Breast... | Nab-Paclitaxel Paclitaxel Docetaxel Phesgo T-DM1 Pertuzumab Trastuzumab Der... Trastuzumab Sub... Tucatinib Trastuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer | NCT06172127 | HER2-positive B... | Trastuzumab der... Phesgo 1,200 MG... Phesgo 600 MG /... | 18 Years - | MedSIR | |
| Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade | NCT06068985 | Breast Cancer HER2-positive B... | PHESGO | 18 Years - 80 Years | Latin American Cooperative Oncology Group | |
| The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | NCT06439693 | Breast Cancer F... Breast Cancer Breast Cancer M... Estrogen Recept... HER2-positive B... Stage IV Breast... | Nab-Paclitaxel Paclitaxel Docetaxel Phesgo T-DM1 Pertuzumab Trastuzumab Der... Trastuzumab Sub... Tucatinib Trastuzumab | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
